ReviewPostepy dermatologii i alergologii2013
Antifungal agents commonly used in the superficial and mucosal candidiasis treatment: mode of action and resistance development.
Review in Postepy dermatologii i alergologii, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 121 citations in OpenAlex.
- Use of Novasomes as a Vesicular Carrier for Improving the Topical Delivery of Terconazole: In Vitro Characterization, In Vivo Assessment and Exploratory Clinical Experimentation.International journal of nanomedicine · 2021Trial
- Essential oil-based hydrogels for oral candidiasis: preliminary formulation development, antifungal efficacy, and computational analysis via Monte Carlo simulation.Frontiers in cellular and infection microbiology · 2026Article
- Molecular mechanisms, pathogenesis and therapeutic advances ofFrontiers in cellular and infection microbiology · 2026Review
- The role of biogenic aluminium oxide nanoparticles (AlScientific reports · 2025Article
- Adulteration of Sports Supplements with Anabolic Steroids-From Innocent Athlete to Vicious Cheater.Nutrients · 2025Review
- Beyond Conventional Antifungals: Combating Resistance Through Novel Therapeutic Pathways.Pharmaceuticals (Basel, Switzerland) · 2025Review
- All Properties of Infertility Microbiome in a Review Article.Journal of clinical laboratory analysis · 2025Review
- The Antifungal Potential of Ozonated Extra-Virgin Olive Oil AgainstBiomolecules · 2024Article
- Saponaria officinalis saponins as a factor increasing permeability of Candida yeasts' biomembrane.World journal of microbiology & biotechnology · 2024Article
- Targeting yeast topoisomerase II by imidazo and triazoloacridinone derivatives resulting in their antifungal activity.Scientific reports · 2024Article
- Antifungal Efficacy of Ganoderma lucidum and Clotrimazole for Treatment of Denture Stomatitis: A Randomized Clinical Trial.Frontiers in dentistry · 2024Article
- Microbial Dysbiosis and Male Infertility: Understanding the Impact and Exploring Therapeutic Interventions.Journal of personalized medicine · 2023Review
- OMICS and Other Advanced Technologies in Mycological Applications.Journal of fungi (Basel, Switzerland) · 2023Review
- Electrospun Poly (Vinyl Alcohol) Nanofibrous Mat Loaded with Green Propolis Extract, Chitosan and Nystatin as an Innovative Wound Dressing Material.Journal of pharmaceutical innovation · 2022Article
- Petrositis caused by fluconazole-resistant candida: case report and literature review.BMC infectious diseases · 2022Review
- Small, Cationic Antifungal Proteins from Filamentous Fungi InhibitMicrobiology spectrum · 2022Article
- Synergistic effect of thymoquinone and nystatin in the treatment of oral candidiasis; an in vitro study.Odontology · 2022Article
- Effect ofCurrent medical mycology · 2021Article
- Does Systemic Methotrexate Therapy Induce Azole Resistance among EndogenousAntibiotics (Basel, Switzerland) · 2021Article
- The Antimicrobial Activity of Omiganan Alone and In Combination againstAntibiotics (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent progress in medical sciences and therapy resulted in an increased number of immunocompromised individuals. Candida albicans is the leading opportunistic fungal pathogen causing infections in humans, ranging from superficial mucosal lesions to disseminated or bloodstream candidiasis. Superficial candidiasis not always presents a risk to the life of the infected host, however it significantly lowers the quality of life. Superficial Candida infections are difficult to treat and their frequency of occurrence is currently rising. To implement successful treatment doctors should be up to date with better understanding of C. albicans resistance mechanisms. Despite high frequency of Candida infections there is a limited number of antimycotics available for therapy. This review focuses on current understanding of the mode of action and resistance mechanisms to conventional and emerging antifungal agents for treatment of superficial and mucosal candidiasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.